Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Formulation C ODT · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Viagra 50 mg tablet, administered with water. | ACTIVE_COMPARATOR | - |
| Formulation B ODT tablet 50 mg, administered without water. | EXPERIMENTAL | - |
| Formulation C ODT tablet 50 mg, administered without water. | EXPERIMENTAL | - |
| Formulation D ODT tablet 50 mg, administered without water. | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Viagra 50 mg tablet | DRUG | Commercial tablet, 50 mg, single dose administered with water |
| Formulation B ODT tablet 50 mg | DRUG | Oral disintegrating tablet (ODT), 50 mg, single dose administered without water |
| Formulation C ODT tablet 50 mg | DRUG | ODT, 50 mg, single dose administered without water |
| Formulation D ODT tablet 50 mg | DRUG | ODT, 50 mg, single dose, administered without water |
Inclusion Criteria: * Healthy subjects * Weight: BMI from 17.5 to 30.5 Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies,...
Formulation C ODT is an oral disintegrating tablet formulation developed by Pfizer, Inc. (PFE). It is a small molecule product candidate that has been studied in a Phase 1 clinical trial. The tablet is also known as Formulation C ODT tablet 50 mg.
Formulation C ODT is made by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the developer of this oral disintegrating tablet formulation.
Formulation C ODT is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently listed as active in any ongoing trials. It is an investigational formulation and has not been approved by the FDA.
Formulation C ODT has been studied in one completed Phase 1 clinical trial, NCT00950404, titled "Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet." The trial enrolled 16 healthy adult volunteers in the United States and used an active-controlled, randomized design.